Patients with non-communicable diseases have a reason for hope after a global drugs maker agreed to ease access to life-saving medicines.
Boehringer Ingelheim has signed a deal with Mission for Essential Drugs and Supplies to expand a key programme that makes it easy for patients to get the drugs they need.
The deal covers medication for type 2 diabetes and hypertension while strengthening local healthcare capacity through strategic collaboration.
The deal is timely as recent research shows NCDs account for 27 per cent of all deaths.
In addition to providing access to medicines at subsidised costs, Boehringer and Meds will raise awareness of type 2 diabetes and hypertension.
Accessing medicine for these diseases is a challenge for many patients due to limited availability in public hospitals, high costs, and unavailability in rural areas where most elderly patients live.
The deal expands the access to healthcare programme targeting underserved communities.
Launched in September 2022, it aims to enhance disease management, provide medical treatments through subsidised pricing, and ensure patient adherence to medication.
As of December 2024, Boehringer’s programme had engaged more than 200 physicians, enrolled over 1,500 patients and collaborated with 15 hospitals in Kenya.
Boehringer Ingelheim, a family-owned Dutch company working on breakthrough therapies that transform lives, was founded in 1885.
It has more than 53,000 employees serving over 130 markets in human and animal health.
Boehringer’s sustainable development for generations framework is committed to creating value in areas of unmet medical need to enable a healthier, sustainable and more equitable future.
Comments 0
Sign in to join the conversation
Sign In Create AccountNo comments yet. Be the first to share your thoughts!